The scientist’s investigation covers issues in Internal medicine, Pharmacology, Hemodynamics, Endocrinology and Anesthesia. The various areas that Hans-Georg Eichler examines in his Internal medicine study include Number needed to treat and Cardiology. The study incorporates disciplines such as Alternative medicine, Clinical trial, Reimbursement and Immunology in addition to Pharmacology.
His Hemodynamics research is multidisciplinary, relying on both Blood flow, Intraocular pressure, Timolol and Retinal, Fundus. His Endocrinology study which covers Platelet that intersects with Aspirin. In his study, Hydroxyethyl starch, Perfusion, Fibrinolysis and Albumin is strongly linked to Crossover study, which falls under the umbrella field of Anesthesia.
Hans-Georg Eichler mainly investigates Internal medicine, Endocrinology, Pharmacology, Anesthesia and Hemodynamics. His studies link Cardiology with Internal medicine. Hans-Georg Eichler interconnects Platelet and Vein in the investigation of issues within Endocrinology.
His Pharmacology research integrates issues from Anticoagulant, Alternative medicine and Immunology. His biological study spans a wide range of topics, including Placebo and Crossover study. His work carried out in the field of Hemodynamics brings together such families of science as Blood flow, Ophthalmology, Blood pressure, Fundus and Vasodilation.
Hans-Georg Eichler mainly focuses on MEDLINE, Clinical trial, Risk analysis, Agency and Public relations. His study in MEDLINE is interdisciplinary in nature, drawing from both Health technology, Data mining, Randomized controlled trial, Marketing authorization and Harm. Hans-Georg Eichler has researched Clinical trial in several fields, including Psychological intervention, Treatment outcome, Intensive care medicine, Alternative medicine and Pharmacology.
When carried out as part of a general Pharmacology research project, his work on Pharmacokinetics is frequently linked to work in Information source, therefore connecting diverse disciplines of study. The concepts of his Risk analysis study are interwoven with issues in Clinical study design, Drug pricing, Drug development and Licensure. His research in Public relations intersects with topics in Government, Private sector and Reflection.
His main research concerns MEDLINE, Clinical trial, Agency, Pharmacology and Drug. His MEDLINE research incorporates elements of Health technology, Data mining, Risk analysis, Marketing authorization and Harm. His work deals with themes such as Alternative medicine, Transparency and Randomized controlled trial, which intersect with Clinical trial.
His Randomized controlled trial research incorporates themes from Cost–benefit analysis, Treatment outcome and Medical physics. His Pharmacology research is multidisciplinary, incorporating elements of International trade and Drug discovery. His work on Drug approval as part of general Drug study is frequently linked to Public economics, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.
Burkhard Jansen;Hermine Schlagbauer-Wadl;Bob D. Brown;Robert N. Bryan.
Nature Medicine (1998)
Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
Olga Geling;Hans-Georg Eichler.
Journal of Clinical Oncology (2005)
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.
Gu¨nter Klappacher;Patrick Franzen;Doris Haab;Mohammad Mehrabi.
American Journal of Cardiology (1995)
Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension.
Gabriele Fuchsjäger-Mayrl;Beate Wally;Michael Georgopoulos;Georg Rainer.
Investigative Ophthalmology & Visual Science (2004)
Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
Hans-Georg Eichler;Eric Abadie;Eric Abadie;Alasdair Breckenridge;Bruno Flamion.
Nature Reviews Drug Discovery (2011)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler;Francesco Pignatti;Bruno Flamion;Hubert Leufkens.
Nature Reviews Drug Discovery (2008)
Paroxetine decreases platelet serotonin storage and platelet function in human beings.
Nicole Hergovich;Martin Aigner;Hans‐Georg Eichler;Jesusa Entlicher.
Clinical Pharmacology & Therapeutics (2000)
Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin.
Bernd Jilma;Andrew Blann;Thomas Pernerstorfer;Petra Stohlawetz.
American Journal of Respiratory and Critical Care Medicine (1999)
Evaluation of the Zeiss retinal vessel analyser.
Kaija Polak;Guido Dorner;Barbara Kiss;Elzbieta Polska.
British Journal of Ophthalmology (2000)
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Hans-Georg Eichler;Brigitte Bloechl-Daum;Eric Abadie;David Barnett.
Nature Reviews Drug Discovery (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: